HOME >> BIOLOGY >> NEWS
JCI table of contents November, 2005

EDITOR'S PICK
A NOVEL MECHANISM OF ACTION FOR LEAD ANTI-TUMOR AGENT

Anti-angiogenic agents have been successful in the clinic for blocking the growth of solid tumors. However, these agents used in combination with chemotherapy have improved the survival of patients with cancers by only several months. Therefore, identification of unrecognized angiogenic pathways that selectively support tumor neo-vessel assembly will increase the efficacy of anti-angiogenic or anti-vascular therapy.

The prototypical vascular targeting agent combretastatin A4 phosphate (CA4P) exerts its anti-angiogenic effect by targeting unstable budding tumor neo-vessels. CA4P is currently being studied in clinical trials in oncology.

In a paper appearing online on October 6 in advance of print publication of the November issue of the Journal of Clinical Investigation, Shahin Rafii and colleagues from Cornell University provide important mechanistic data demonstrating how CA4P has anti-tumor and anti-angiogenic activity.

The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.

Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.

TITLE: Combretastatin A4 phosphate disrupts tumor vasculature and growth by interfering with vascular endothelial-cadherin
'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
6-Oct-2005


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/19/2019)... ... 2019 , ... The Laser Institute (LIA)'s 38th ... held in Orlando, Florida and featured the conference’s many firsts. A meeting of ... with a deeper industry foci, more expansive technical sessions, and a new Business ...
(Date:10/17/2019)... , ... October 15, 2019 , ... ... Media for the Microbiological Community”. , Microbiology International currently manufactures ready-to-use culture broth ... also offers pre-poured agar plates & liquid supplements. , This major step underpins ...
(Date:10/17/2019)... ... October 16, 2019 , ... The International Society for ... Baseline® Guide: Water and Steam Systems (Third Edition) . This guide provides in-depth ... systems. Industry professionals can better understand Good Manufacturing Practices (GMPs), to comply with ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 02, 2019 , ... Today marked the ... is enabling clinical program outsourcing success by cultivating radical improvements in leadership, staff, ... veteran executive Brenda Reese, phaseUP™ brings clients deep, broad and unique expertise in ...
(Date:10/3/2019)... ... 03, 2019 , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical ... L. Sherley, M.D., Ph.D., discussed important design factors that currently limit the success of ... and suppliers of clinical trials, in his talk Dr. Sherley focused on ...
(Date:9/24/2019)... N.J. and WALTHAM, Mass. (PRWEB) , ... ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing ... Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development ...
(Date:9/22/2019)... Ore. (PRWEB) , ... September 20, 2019 , ... ... commercial launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . BDNF ... nervous systems. BDNF stimulates the growth and differentiation of new neurons in the ...
Breaking Biology Technology:
Cached News: